JPWO2020252208A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020252208A5 JPWO2020252208A5 JP2021573387A JP2021573387A JPWO2020252208A5 JP WO2020252208 A5 JPWO2020252208 A5 JP WO2020252208A5 JP 2021573387 A JP2021573387 A JP 2021573387A JP 2021573387 A JP2021573387 A JP 2021573387A JP WO2020252208 A5 JPWO2020252208 A5 JP WO2020252208A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- binding domain
- antigen
- domain
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962860055P | 2019-06-11 | 2019-06-11 | |
| US62/860,055 | 2019-06-11 | ||
| US201962908978P | 2019-10-01 | 2019-10-01 | |
| US62/908,978 | 2019-10-01 | ||
| PCT/US2020/037312 WO2020252208A2 (en) | 2019-06-11 | 2020-06-11 | Macrophage specific engager compositions and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022536684A JP2022536684A (ja) | 2022-08-18 |
| JPWO2020252208A5 true JPWO2020252208A5 (pt) | 2023-06-16 |
Family
ID=73781864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573387A Pending JP2022536684A (ja) | 2019-06-11 | 2020-06-11 | マクロファージ特異的エンゲージャー組成物およびその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220241428A1 (pt) |
| EP (1) | EP3983007A4 (pt) |
| JP (1) | JP2022536684A (pt) |
| KR (1) | KR20220048988A (pt) |
| CN (1) | CN114340681A (pt) |
| AU (1) | AU2020292339A1 (pt) |
| BR (1) | BR112021024978A2 (pt) |
| CA (1) | CA3140875A1 (pt) |
| GB (1) | GB2603044B (pt) |
| IL (1) | IL288788A (pt) |
| MX (1) | MX2021015411A (pt) |
| WO (1) | WO2020252208A2 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| MX2022002613A (es) | 2019-09-03 | 2022-06-02 | Myeloid Therapeutics Inc | Metodos y composiciones para la integracion del genoma. |
| AU2021376354A1 (en) | 2020-11-04 | 2023-06-22 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
| US11572407B2 (en) | 2020-11-18 | 2023-02-07 | Pionyr Immunotherapeutics, Inc. | Anti-MARCO antibodies and uses thereof |
| WO2022197949A2 (en) | 2021-03-17 | 2022-09-22 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
| EP4399315A2 (en) * | 2021-09-10 | 2024-07-17 | Myeloid Therapeutics, Inc. | Macrophage specific engager compositions and methods of use thereof |
| WO2023215814A2 (en) * | 2022-05-04 | 2023-11-09 | The Scripps Research Institute | Sialidase fusion molecules and related uses |
| CN116059348A (zh) * | 2022-09-16 | 2023-05-05 | 四川大学华西医院 | 基于nkg2d的细胞接合器分子在清除衰老细胞中的应用 |
| CN117205152B (zh) * | 2023-02-23 | 2024-04-09 | 南京大学 | 一种药物载体，其制备方法及其在疾病治疗中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9022788D0 (en) | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
| US6146850A (en) * | 1991-11-04 | 2000-11-14 | Xoma Corporation | Proteins encoding gelonin sequences |
| WO1998005795A1 (en) * | 1996-08-02 | 1998-02-12 | The Center For Blood Research, Inc. | Enrichment of dendritic cells from blood |
| US20090285757A1 (en) * | 2008-05-16 | 2009-11-19 | Northeastern University | Methods of targeting cells for diagnosis and therapy |
| EP2332994A1 (en) * | 2009-12-09 | 2011-06-15 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Trispecific therapeutics against acute myeloid leukaemia |
| CA3197849A1 (en) * | 2014-12-29 | 2016-07-07 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| HUE045866T2 (hu) * | 2015-05-04 | 2020-01-28 | Affimed Gmbh | CD30XCD16A antitest kombinálása anti-PD-1-antagonista antitesttel terápiához |
| CN107634924B (zh) * | 2016-07-18 | 2020-08-11 | 中兴通讯股份有限公司 | 同步信号的发送、接收方法及装置、传输系统 |
| EP3574018A4 (en) * | 2017-01-27 | 2020-10-07 | Silverback Therapeutics, Inc. | CONJUGATES TARGETING TUMORS AND THEIR METHODS OF USE |
| EA201991632A1 (ru) * | 2017-02-28 | 2020-03-12 | Аффимед Гмбх | Комбинация антитела против cd16a с цитокином |
| WO2018222506A1 (en) * | 2017-05-27 | 2018-12-06 | Immune-Onc Therapeutics, Inc. | Modulation of immunoglobulin-a-positive cells |
| WO2018231871A1 (en) * | 2017-06-12 | 2018-12-20 | Emory University | T-cell antigen targeted chimeric antigen receptor (car) and uses in cell therapies |
-
2020
- 2020-06-11 JP JP2021573387A patent/JP2022536684A/ja active Pending
- 2020-06-11 CN CN202080057211.2A patent/CN114340681A/zh active Pending
- 2020-06-11 CA CA3140875A patent/CA3140875A1/en active Pending
- 2020-06-11 MX MX2021015411A patent/MX2021015411A/es unknown
- 2020-06-11 BR BR112021024978A patent/BR112021024978A2/pt unknown
- 2020-06-11 WO PCT/US2020/037312 patent/WO2020252208A2/en unknown
- 2020-06-11 GB GB2118129.2A patent/GB2603044B/en active Active
- 2020-06-11 AU AU2020292339A patent/AU2020292339A1/en active Pending
- 2020-06-11 EP EP20822720.7A patent/EP3983007A4/en active Pending
- 2020-06-11 KR KR1020227000747A patent/KR20220048988A/ko unknown
- 2020-06-11 US US17/618,349 patent/US20220241428A1/en active Pending
-
2021
- 2021-12-08 IL IL288788A patent/IL288788A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2603044A (en) | Macrophage specific engager compositions and methods of use thereof | |
| Klein et al. | Engineering therapeutic bispecific antibodies using CrossMab technology | |
| JPWO2020252208A5 (pt) | ||
| Kang et al. | Boosting therapeutic potency of antibodies by taming Fc domain functions | |
| GB2600834A (en) | Engineered chimeric fusion protein compositions and methods of use thereof | |
| Chen et al. | Bispecific antibodies in cancer immunotherapy | |
| Weiner et al. | Monoclonal antibodies: versatile platforms for cancer immunotherapy | |
| CN107074957A (zh) | 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法 | |
| Sanz et al. | Antibodies and gene therapy: teaching old ‘magic bullets’ new tricks | |
| RU2020120411A (ru) | Триспецифические связывающие молекулы, направленные против опухолеассоциированных антигенов, и пути их применения | |
| JP2020515256A5 (pt) | ||
| GB2519786A (en) | Multivalent antigen-binding protein molecules | |
| JP2016514676A (ja) | 四価二重特異性抗体 | |
| CN105658668A (zh) | 分子 | |
| CN105407902A (zh) | 溶瘤病毒 | |
| Li et al. | CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy | |
| Kim et al. | Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics | |
| JPWO2019104075A5 (pt) | ||
| US20200405833A1 (en) | Bispecific egfr/cd16 antigen-binding protein | |
| TW202122576A (zh) | 具抗原專一性的t細胞及其用途 | |
| JP2018526453A5 (pt) | ||
| US20200338161A1 (en) | Btnl9 and ermap as novel inhibitors of the immune system for immunotherapies | |
| Fenis et al. | New immune cell engagers for cancer immunotherapy | |
| JPWO2020223550A5 (pt) | ||
| JP2022524906A (ja) | 細胞免疫療法の組み合わせ |